Stopping unnecessary heart medications in older adults with Alzheimer's disease and related dementias
Official title: Deprescribing Cardiovascular Medications among Persons with and without Alzheimer's Disease and Related Dementias in Long-Term Care
Funded at Palo Alto Veterans Instit for Research · NIH-11122300 · Data updated 2026-11-12
This study is looking at whether stopping certain heart medications, like aspirin and statins, can be helpful for older nursing home residents with Alzheimer's and similar conditions, to see if it might reduce risks without losing important benefits.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Palo Alto Veterans Instit for Research NIH-funded |
| Lab location | 1 site (Palo Alto, United States) |
| Project start | May 15, 2019 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $677,931 |
| NIH project number | 5R01AG062568-03 |
| Project ID | NIH-11122300 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include nursing home residents aged 65 and older, particularly those diagnosed with Alzheimer's disease or related dementias.
✕Less likely to help
Patients who are younger than 65 or those without Alzheimer's disease or related dementias may not receive benefit from this research.
What this research studies
This research investigates the process of deprescribing cardiovascular medications in nursing home residents, particularly those with Alzheimer's disease and related dementias. It aims to determine the effects and benefits of stopping medications like aspirin and statins in patients who may not gain significant advantages from them due to their condition. By analyzing a large cohort of approximately 150,000 residents aged 65 and older in Veteran's Health Administration nursing homes, the study seeks to provide evidence on which patients could benefit from this approach. The research will help clarify the balance between the risks of medication-related adverse events and the potential benefits of these medications.
Why it matters
Potential benefit: If successful, this research could lead to safer medication practices and improved quality of life for older adults with Alzheimer's disease and related dementias.
How similar studies have gone: While many studies have focused on starting cardiovascular medications, few have explored the effects of deprescribing, making this research a novel approach.
Where this research is happening
-
Palo Alto Veterans Instit for Research
Palo Alto, United States Active
Researchers
- Principal investigator: Liu, Christine Kee — Palo Alto Veterans Instit for Research
- Study coordinator: Liu, Christine Kee
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.